Organ-on-Chip & Organoids
Hesperos Human-on-a-Chip
by Hesperos, Inc.
Serum-free multi-organ human-on-a-chip platform for systemic drug efficacy and toxicity assessment
Category
Organ-on-Chip & Organoids
Founded
2016
Headquarters
Orlando, FL, USA
Overview
Hesperos develops a unique serum-free, multi-organ human-on-a-chip platform based on technology pioneered at Cornell University and the University of Central Florida. The system uses a recirculating pumpless microfluidic design in which multiple human tissue modules — including cardiac, skeletal muscle, liver, neural, and neuromuscular junction constructs — are connected by a common media flow to mimic systemic drug circulation and organ crosstalk. All tissues are maintained without animal serum, using fully defined human media formulations that eliminate xenobiotic interference in drug metabolism studies. Pharmaceutical developers and contract research organizations use Hesperos's platform to assess drug efficacy and multi-organ toxicity in a single integrated experiment, capturing secondary effects that isolated single-organ models cannot detect. The platform has been applied to programs in cardiac safety (detecting arrhythmia and contractility changes), neuromuscular disease modeling (myasthenia gravis, Pompe disease), and oncology drug screening. Hesperos primarily operates as a contract research service provider, running studies on behalf of pharma clients. What sets Hesperos apart is its serum-free approach and multi-organ integration: by eliminating serum, the platform achieves human-relevant pharmacokinetics without confounding binding proteins and growth factors present in animal serum. The company's functional readouts — contractile force measurement from cardiac and skeletal muscle tissue — provide physiological endpoints beyond cell viability or biomarker release. Hesperos has received multiple NIH SBIR grants and DARPA funding supporting its development of complex human tissue systems.
Key Features
High-Throughput Organoid Screening
Automated platforms test thousands of compounds per experiment on organoid arrays.
Patient-Derived Organoids
Generate organoids from patient tissues for personalized drug screening and precision oncology.
Multi-Organ Systems
Connected organ chip models simulate drug ADME across multiple organ systems simultaneously.
Microfluidic Organ Chips
Recapitulate human tissue-level physiology in microfluidic devices for predictive drug testing.
Bioprinting Integration
3D bioprinting of tissue constructs with controlled architecture and cellular composition.
Pros & Cons
Pros
- +Real-time sensing and imaging capture dynamic tissue responses to drug exposure
- +Standardized culture protocols ensure reproducibility across labs and experimental batches
- +High-throughput organoid screening platforms test thousands of compounds per experiment
- +Reduces animal testing requirements while improving human-relevant toxicity predictions
- +Patient-derived organoids enable personalized drug screening for precision oncology applications
- +Multi-organ systems model drug absorption, distribution, metabolism, and excretion in vitro
- +Microfluidic organ chips recapitulate human tissue-level physiology for predictive drug testing
Cons
- −Organoid variability between batches and labs creates reproducibility challenges
- −Specialized equipment and expertise required for organ chip operation limits broad adoption
- −Regulatory acceptance of organ-chip data as replacement for animal testing is still developing
- −High per-unit costs for microfluidic chips limit throughput compared to traditional cell culture
Use Cases
Research Workflow Optimization
AI-powered optimization of research workflows to accelerate discovery timelines and improve reproducibility.
Data Analysis & Insights
Machine learning analysis of complex biological datasets to extract actionable insights and identify patterns.
Collaboration & Knowledge Management
Platform-enabled collaboration across distributed research teams with integrated data sharing and knowledge capture.